Skip to main content

Biomea Fusion Inc

For the period ended Jun 30, 2024. Filed Jul 31, 2024.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2024 · Filed Jul 31, 2024

BMEA$0.55-8.1%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Condensed Statements of Cash Flows

(in thousands)

Six Months Ended
June 30,
20242023
Operating Activities
Net loss$(76,337)$(53,942)
Adjustments to reconcile net loss to net cash used in operating activities
Depreciation expense843676
Non-cash operating lease expense1,3761,285
Stock-based compensation expense9,8626,669
Net amortization of premiums and accretion of discounts on investments—1
Changes in operating assets and liabilities:
Prepaid expenses and other current assets(687)1,742
Other assets(1,244)(761)
Accounts payable(1,058)(163)
Accrued expenses and other current liabilities2,503(4,171)
Operating lease liabilities69(1,192)
Net cash used in operating activities(64,673)(49,856)
Investing Activities
Purchase of property and equipment(94)(3,323)
Maturities of investments—1,150
Net cash used in investing activities(94)(2,173)
Financing Activities
Proceeds from issuance of common stock from public offering, net of offering costs—161,803
Proceeds from stock option exercise and purchases under the employee stock purchase plan1,1861,235
Net cash provided by financing activities1,186163,038
Net (decrease) increase in cash, cash equivalents, and restricted cash(63,581)111,009
Cash, cash equivalents, and restricted cash at the beginning of the period177,236112,250
Cash, cash equivalents, and restricted cash at the end of the period$113,655$223,259
Non-cash financing and investing activities:
Acquisition of operating lease right-of-use assets$—$11,639
Acquisition of property and equipment in accounts payable and accrued liabilities$35$28
Reconciliation of cash and cash equivalents, and restricted cash:
Cash and cash equivalents$113,286$222,908
Restricted cash369351
Total cash and cash equivalents, and restricted cash$113,655$223,259
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.